Our motivation. His glaucoma.
Image is designed to represent glaucoma visual impairment and is
not intended to be medically accurate. For illustrative purposes only.
© 2013 Santen Pharmaceutical Co., Ltd. All rights reserved. SAN-272.00 07/12
At Santen, our single focus in ophthalmology enables
research of novel therapies in glaucoma, uveitis, and
dry eye/corneal disorders—therapies determined to
challenge eye disease, one patient at a time.
Inspiring ophthalmic medicines
To explore what's new at
Santen, scan this code with
your mobile device or visit
www.santeninc.com.
s new at o explore what' T
research of novel therapies in glaucoma, uveitis, and
At Santen, our single focus in ophthalmology enables
research of novel therapies in glaucoma, uveitis, and
At Santen, our single focus in ophthalmology enables
research of novel therapies in glaucoma, uveitis, and
At Santen, our single focus in ophthalmology enables
. .santeninc.com www
your mobile device or visit
Santen, scan this code with
challenge eye disease, one patient at a time.
dry eye/corneal disorders—therapies determined to
challenge eye disease, one patient at a time.
Inspiring ophthalmic medicines
dry eye/corneal disorders—therapies determined to
challenge eye disease, one patient at a time.
Inspiring ophthalmic medicines
dry eye/corneal disorders—therapies determined to
3 Santen Pharmaceutical Co., Ltd. All rights r © 201 eserved. SAN-272.00 3 Santen Pharmaceutical Co., Ltd. All rights r 07/12
o
eserved. SAN-272.00
